表紙
市場調查報告書

勃起障礙治療藥市場:全球產業分析,規模,佔有率,成長,趨勢,預測

Erectile Dysfunction Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

出版商 Transparency Market Research 商品編碼 662983
出版日期 內容資訊 英文 196 Pages
商品交期: 最快1-2個工作天內
價格
勃起障礙治療藥市場:全球產業分析,規模,佔有率,成長,趨勢,預測 Erectile Dysfunction Drugs Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
出版日期: 2018年06月05日內容資訊: 英文 196 Pages
簡介

本報告提供全球勃起障礙治療藥市場相關調查,彙整市場現狀與成長預測,各藥物,流通管道,各地區趨勢,及加入此市場的主要企業的簡介等資料。

第1章 序論

第2章 假設和調查方法

第3章 摘要整理

第4章 市場概要

  • 簡介
  • 概要

第5章 市場預測

  • 市場趨勢
    • 促進要素
    • 阻礙要素
    • 機會
    • 機會分析
    • 趨勢
  • 市場分析與預測
  • 波特五力分析
  • 市場價值連鎖分析
  • 開發平台分析
  • 今後預測

第6章 各藥物市場分析與預測

  • 簡介和定義
  • 調查結果/發展
  • 市場價值預測
  • 市場預測
    • Viagra
    • Cialis
    • Staxyn/Levitra
    • Stendra/Spedra
  • 市場魅力度

第7章 各流通管道市場分析與預測

  • 簡介和定義
  • 調查結果/發展
  • 市場價值預測
  • 市場預測
    • 院內藥局
    • 零售藥局
    • 線上藥局
  • 市場魅力度

第8章 各地區市場

  • 主要調查結果
  • 市場價值預測
    • 北美
    • 歐洲
    • 亞太地區
    • 南美
    • 中東·非洲
  • 市場魅力度

第9章 北美

第10章 歐洲

第11章 亞太地區

第12章 南美

第13章 中東·非洲

第14章 競爭環境

  • 市場參與企業
  • 各企業市場佔有率分析
  • 競爭商務策略
  • 企業簡介
目錄

Title:
Erectile Dysfunction (ED) Drugs Market (Drug - Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026.

Erectile Dysfunction (ED) Drugs Market - Overview

This report studies the current as well as future prospects of the global erectile dysfunction (ED) drugs market. Stakeholders of the market include companies and intermediaries engaged in the manufacture, commercialization, and marketing of therapeutic drugs for the treatment of erectile dysfunction, as well as new players planning to enter the market. The report comprises an elaborate executive summary along with a market snapshot providing overall information of various segments considered in the scope of the study. The section also provides overall information and data analysis of the global erectile dysfunction drugs market with respect to the leading segments based on drug class, distribution channel, and region.

The global erectile dysfunction drugs market has been segmented based on drug, distribution channel, and region. In terms of drug, the market has been classified into Viagra, Cialis, Staxyn/Levitra, Stendra/Spedra, and others. Based on distribution channel, the global erectile dysfunction drugs market has been categorized into hospital pharmacies, retail pharmacies, and online pharmacies.

Each of the market segments has been extensively analyzed based on market-related factors such as increasing incidence and prevalence of erectile dysfunction. Moreover, historical year-on-year growth has been taken into consideration while estimating the market size. The market size and forecast in terms of US$ Mn for each segment have been provided for the period from 2016 to 2026. The report also provides the compound annual growth rate (CAGR %) for each segment for the forecast period from 2018 to 2026, considering 2017 as the base year.

The overview section of the report explores the market dynamics such as drivers, restraints, opportunities, and pipeline drugs that currently have a strong impact on the global erectile dysfunction drugs market and is likely to influence the market in the near future. Market attractiveness analysis has been provided in the market overview section in order to explain the intensity of competition in the market across different regions. The competitive scenario among different market players is evaluated through market share analysis in the competitive landscape section of the report. All these factors are expected to help market players take strategic decisions to strengthen their positions and enhance their shares in the global erectile dysfunction drugs market.

Geographically, the global erectile dysfunction drugs market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The market size and forecast for each of these regions have been provided for the period from 2016 to 2026, along with their respective CAGR for the forecast period from 2018 to 2026, considering 2017 as the base year. The report provides market size and forecast for the major countries in the respective regions. A detailed qualitative analysis of factors responsible for driving and restraining the market and future opportunities has been provided in the market overview section. It also provides market attractiveness analysis and market share analysis of key players, thereby presenting a thorough examination of the overall competitive scenario of the global erectile dysfunction drugs market.

Major players operating in the global erectile dysfunction drugs market are Pfizer, Inc., Dong-A ST Co., Ltd., Eli Lilly and Company, Bayer AG, VIVUS, Inc., SK Chemicals, Meda Pharmaceuticals, Inc., Cristalia Produtos Quimicos Farmaceuticos Ltda., Apricus Biosciences, Inc., and Teva Pharmaceutical Industries Ltd.

The global erectile dysfunction drugs market has been segmented as follows:

Global Erectile Dysfunction Drugs Market, By Drug

  • Viagra
  • Cialis
  • Staxyn/Levitra
  • Stendra/Spedra
  • Others

Global Erectile Dysfunction Drugs Market, By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Global Erectile Dysfunction Drugs Market, By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Table of Contents

1. Preface

  • 1.1. Market Segmentation
  • 1.2. Key Research Objectives
  • 1.3. Research Highlights

2. Assumptions and Research Methodology

  • 2.1. Secondary Research Methodology
  • 2.2. Primary Research Methodology
  • 2.3. Analysis Research Methodology

3. Executive Summary: Global Erectile Dysfunction (ED) Drugs Market

4. Market Overview

  • 4.1. Introduction
    • 4.1.1. Drug Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview

5. Market Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
    • 5.1.2. Restraints
    • 5.1.3. Opportunity
    • 5.1.4. Opportunity Analysis
    • 5.1.5. Trends
  • 5.2. Global Erectile Dysfunction Market Analysis and Forecasts, 2016-2026
  • 5.3. Porter's Five Forces Analysis
  • 5.4. Erectile Dysfunction Drugs Market Value Chain Analysis
  • 5.5. Pipeline Analysis
    • 5.5.1. Discovery
    • 5.5.2. Preclinical
    • 5.5.3. IND (Investigational New Drug)
    • 5.5.4. Phase I
    • 5.5.5. Phase I/II
    • 5.5.6. Phase II
    • 5.5.7. Phase III
    • 5.5.8. Pre-registration
  • 5.6. Global Erectile Dysfunction (ED) Drug Market Outlook

6. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Drug

  • 6.1. Introduction & Definition
  • 6.2. Key Findings / Developments
  • 6.3. Market Value Forecast, by Drug, 2016-2026
    • 6.3.1. Viagra
    • 6.3.2. Cialis
    • 6.3.3. Staxyn/Levitra
    • 6.3.4. Stendra/Spedra
    • 6.3.5. Others
  • 6.4. Market Attractiveness, by Drug

7. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Distribution Channel

  • 7.1. Introduction & Definition
  • 7.2. Key Findings / Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2016-2026
    • 7.3.1. Hospital Pharmacy
    • 7.3.2. Retail Pharmacy
    • 7.3.3. Online Pharmacy
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Erectile Dysfunction (ED) Drugs Market Analysis and Forecasts, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Country/Region

9. North America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Drug, 2016-2026
    • 9.2.1. Viagra
    • 9.2.2. Cialis
    • 9.2.3. Staxyn/Levitra
    • 9.2.4. Stendra/Spedra
    • 9.2.5. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2016-2026
    • 9.3.1. Hospital Pharmacy
    • 9.3.2. Retail Pharmacy
    • 9.3.3. Online Pharmacy
  • 9.4. Market Value Forecast, by Country, 2016-2026
    • 9.4.1. U.S.
    • 9.4.2. Canada

10. Europe Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Drug, 2016-2026
    • 10.2.1. Viagra
    • 10.2.2. Cialis
    • 10.2.3. Staxyn/Levitra
    • 10.2.4. Stendra/Spedra
    • 10.2.5. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2016-2026
    • 10.3.1. Hospital Pharmacy
    • 10.3.2. Retail Pharmacy
    • 10.3.3. Online Pharmacy
  • 10.4. Market Value Forecast, by Country/Sub-region, 2016-2026
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Spain
    • 10.4.5. Italy
    • 10.4.6. Rest of Europe

11. Asia Pacific Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 11.1.Introduction
    • 11.1.1. Key Findings
  • 11.2.Market Value Forecast, by Drug, 2016-2026
    • 11.2.1. Viagra
    • 11.2.2. Cialis
    • 11.2.3. Staxyn/Levitra
    • 11.2.4. Stendra/Spedra
    • 11.2.5. Others
  • 11.3.Market Value Forecast, by Distribution Channel, 2016-2026
    • 11.3.1. Hospital Pharmacy
    • 11.3.2. Retail Pharmacy
    • 11.3.3. Online Pharmacy
  • 11.4.Market Value Forecast, by Country/Sub-region, 2016-2026
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific

12. Latin America Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 12.1.Introduction
    • 12.1.1. Key Findings
  • 12.2.Market Value Forecast, by Drug, 2016-2026
    • 12.2.1. Viagra
    • 12.2.2. Cialis
    • 12.2.3. Staxyn/Levitra
    • 12.2.4. Stendra/Spedra
    • 12.2.5. Others
  • 12.3.Market Value Forecast, by Distribution Channel, 2016-2026
    • 12.3.1. Hospital Pharmacy
    • 12.3.2. Retail Pharmacy
    • 12.3.3. Online Pharmacy
  • 12.4.Market Value Forecast, by Country/Sub-region, 2016-2026
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America

13. Middle East & Africa Erectile Dysfunction (ED) Drugs Market Analysis and Forecast

  • 13.1.Introduction
    • 13.1.1. Key Findings
  • 13.2.Market Value Forecast, by Drug, 2016-2026
    • 13.2.1. Viagra
    • 13.2.2. Cialis
    • 13.2.3. Staxyn/Levitra
    • 13.2.4. Stendra/Spedra
    • 13.2.5. Others
  • 13.3.Market Value Forecast, by Distribution Channel, 2016-2026
    • 13.3.1. Hospital Pharmacy
    • 13.3.2. Retail Pharmacy
    • 13.3.3. Online Pharmacy
  • 13.4.Market Value Forecast, by Country/Sub-region, 2016-2026
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of companies)
  • 14.2. Market Share Analysis, by Company (2017)
  • 14.3. Competitive Business Strategies
  • 14.4. Company Profiles
    • 14.4.1. Pfizer, Inc.
      • 14.4.1.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.1.2. Product Portfolio
      • 14.4.1.3. SWOT Analysis
      • 14.4.1.4. Strategic Overview
    • 14.4.2. Dong-A ST Co., Ltd.
      • 14.4.2.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.2.2. Product Portfolio
      • 14.4.2.3. SWOT Analysis
      • 14.4.2.4. Strategic Overview
    • 14.4.3. Eli Lilly and Company
      • 14.4.3.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.3.2. Product Portfolio
      • 14.4.3.3. SWOT Analysis
      • 14.4.3.4. Strategic Overview
    • 14.4.4. Bayer AG
      • 14.4.4.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.4.2. Product Portfolio
      • 14.4.4.3. SWOT Analysis
      • 14.4.4.4. Strategic Overview
    • 14.4.5. VIVUS, INC.
      • 14.4.5.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.5.2. Product Portfolio
      • 14.4.5.3. SWOT Analysis
      • 14.4.5.4. Strategic Overview
    • 14.4.6. SK chemicals
      • 14.4.6.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.6.2. Product Portfolio
      • 14.4.6.3. SWOT Analysis
      • 14.4.6.4. Strategic Overview
    • 14.4.7. Meda Pharmaceuticals Inc.
      • 14.4.7.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.7.2. Product Portfolio
      • 14.4.7.3. SWOT Analysis
      • 14.4.7.4. Strategic Overview
    • 14.4.8. Cristalia Produtos Quimicos Farmaceuticos Ltda.
      • 14.4.8.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.8.2. Product Portfolio
      • 14.4.8.3. SWOT Analysis
      • 14.4.8.4. Strategic Overview
    • 14.4.9. Apricus Biosciences, Inc.
      • 14.4.9.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.9.2. Product Portfolio
      • 14.4.9.3. SWOT Analysis
      • 14.4.9.4. Strategic Overview
    • 14.4.10. Teva Pharmaceutical Industries Ltd.
      • 14.4.10.1. Company Overview (HQ, Business Segments, Employee)
      • 14.4.10.2. Product Portfolio
      • 14.4.10.3. SWOT Analysis
      • 14.4.10.4. Strategic Overview

List of Tables:

  • Table 01: Global Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 02: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 03: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Region, 2016-2026
  • Table 04: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country, 2016-2026
  • Table 05: North America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 06: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 07: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 08: Europe Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 9: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 10: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 11: Asia Pacific Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 12: Asia Pacific Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 13: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 14: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 15: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 16: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2016-2026
  • Table 17: Latin America Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, by Drug Class, 2016-2026
  • Table 18: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2016-2026
  • Table 19: Pfizer, Inc. Products Offered
  • Table 20: Pfizer, Inc. Recent Developments
  • Table 21: Dong-A ST Co., Ltd. Products Offered
  • Table 22: Dong-A ST Co., Ltd. Recent Developments
  • Table 23: Eli Lilly and Company Products Offered
  • Table 24: Eli Lilly and Company Recent Developments
  • Table 25: Bayer AG Products Offered
  • Table 26: Bayer AG Recent Developments
  • Table 27: VIVUS, INC. Ltd. Products Offered
  • Table 28: VIVUS, INC. Recent Developments
  • Table 29: SK chemicals Products Offered
  • Table 30: SK chemicals Recent Developments
  • Table 31: Meda Pharmaceuticals Inc. Products Offered
  • Table 32: Meda Pharmaceuticals Inc. Recent Developments
  • Table 33: Cristalia Produtos Quimicos Farmaceuticos Ltda. Products Offered
  • Table 34: Cristalia Produtos Quimicos Farmaceuticos Ltda. Recent Developments
  • Table 35: Apricus Biosciences, Inc. Products Offered
  • Table 36: Apricus Biosciences, Inc. Recent Developments
  • Table 37: Teva Pharmaceutical Industries Ltd. Products Offered

List of Figures:

  • Figure 01: Global Erectile Dysfunction (ED) Drug Market Size (US$ Mn) Forecast, 2016-2026
  • Figure 02: Market Value Share, by Drug Class (2017)
  • Figure 04: Market Value Share, by Distribution Channel (2017)
  • Figure 05: Market Value Share, by Region (2017)
  • Figure 06: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
  • Figure 07: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Viagra, 2016-2026
  • Figure 08: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Cialis, 2016-2026
  • Figure 9: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Staxyn/Levitra, 2016-2026
  • Figure 10: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Stendra/Spedra, 2016-2026
  • Figure 11: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by others, 2016-2026
  • Figure 12: Global Erectile Dysfunction (ED) Drug Market Value Share Analysis, by Distribution channel, 2017 and 2026
  • Figure 13: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Hospital Pharmacy, 2016-2026
  • Figure 14: Global Erectile Dysfunction (ED) Drugs Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Retail Pharmacy, 2016-2026
  • Figure 15: Global Erectile Dysfunction (ED) Drug Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%), by Online Pharmacy, 2016-2026
  • Figure 16: Global Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Region, 2017 and 2026
  • Figure 17: North America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2017-2026
  • Figure 18: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country, 2017 and 2026
  • Figure 19: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
  • Figure 20: North America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2026
  • Figure 21: Europe Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2026
  • Figure 22: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 23: Europe Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
  • Figure 24: Europe Erectile Dysfunction (ED) Drugs Treatment Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 25: Asia Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2026
  • Figure 26: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 27: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 28: Asia Pacific Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 29: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2026
  • Figure 30: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 31: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug Class, 2017 and 2026
  • Figure 32: Middle East & Africa Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 33: Latin America Erectile Dysfunction (ED) Drugs Market Size (US$ Mn) and Y-o-Y Growth (%) Forecast, 2018-2026
  • Figure 34: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
  • Figure 35: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Drug, 2017 and 2026
  • Figure 36: Latin America Erectile Dysfunction (ED) Drugs Market Value Share Analysis, by Distribution Channel, 2017 and 2026
  • Figure 37: Global Erectile Dysfunction (ED) Drugs Market Share Analysis, by Company (2017)
  • Figure 38: Pfizer, Inc. Breakdown of Net Sales, by Region, 2016
  • Figure 39: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2016
  • Figure 40: Pfizer, Inc. R&D Intensity and Sales & Marketing Intensity - Company Level, 2015-2016
  • Figure 41: Dong-A ST Co., Ltd. Breakdown of Net Sales, by Businesses Segment
  • Figure 42: Dong-A ST Co., Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2014-2016
  • Figure 43: Dong-A ST Co., Ltd. R&D Intensity and Sales & Marketing Intensity - Company Level, 2015-2016
  • Figure 44: Eli Lilly and Company Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 45: Eli Lilly and Company R&D Intensity and Sales & Marketing Intensity - Company Level, 2015-2016
  • Figure 46: Eli Lilly and Company Breakdown of Net Sales, by Region (Company Level), 2016
  • Figure 47: Eli Lilly and Company Breakdown of Net Sales, (by Endocrinology Level), 2016
  • Figure 48: Bayer AG Breakdown of Net Sales, by Region, 2017
  • Figure 49: Bayer AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2017
  • Figure 50: Bayer AG R&D Intensity and Net Income (US$ Mn) - Company Level, 2016-2017
  • Figure 51: VIVUS, INC. R&D Intensity and Sales & Marketing Intensity - Company Level, 2015-2016
  • Figure 52: VIVUS, INC. Breakdown of Revenue, by Operation (Company Level), 2017
  • Figure 53: VIVUS, INC. Breakdown of Research and Development Expenses, 2017
  • Figure 54: SK chemicals Consolidated Balance Sheet (US$ Bn), 2016
  • Figure 55: SK chemicals Revenue (US$ Bn) and Y-o-Y Growth (%), 2013-2017
  • Figure 56: SK chemicals R&D Intensity and Net Income (US$ Mn) - Company Level, 2014-2016
  • Figure 57: Meda Pharmaceuticals Inc. Breakdown of Net Sales, by Region, 2015
  • Figure 58: Meda Pharmaceuticals Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2011-2015
  • Figure 59: Meda Pharmaceuticals Inc. Selling, Medicine &business development and administrative expenses (US$ Mn) - Company Level, 2014-2015
  • Figure 60: Apricus Biosciences, Inc. Breakdown of Net Sales, by Region, 2017
  • Figure 61: Apricus Biosciences, Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2013-2016
  • Figure 62: Apricus Biosciences, Inc. R&D and General & administrative (US$ Mn) - Company Level, 2015-2016
  • Figure 63: Teva Pharmaceutical Industries Ltd. Revenue (US$ Bn) & Y-o-Y Growth (%), 2013-2016
  • Figure 64: Teva Pharmaceutical Industries Ltd. R&D Intensity and Sales & Marketing Intensity (%) - Company Level, 2015-2016
  • Figure 65: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, by Region 2016
  • Figure 66: Teva Pharmaceutical Industries Ltd. Breakdown of Net Sales, (Overall Company Level), 2016